Nir Peled

Nir Peled

Kaplan Street
Petah Tiqwa, M 49100, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 199 publications

From matching to facilitation: Reframing AI's role in clinical trial enrollment.

From matching to facilitation: Reframing AI's role in clinical trial enrollment.

Journal: Patterns (New York, N.Y.)

Published: July 15, 2026

De Novo Actionable Genomic Alterations in High-Grade Pulmonary Neuroendocrine Carcinomas: Therapeutic Implications of Targeted Treatment.

De Novo Actionable Genomic Alterations in High-Grade Pulmonary Neuroendocrine Carcinomas: Therapeutic Implications of Targeted Treatment.

Journal: Medical sciences (Basel, Switzerland)

Published: July 03, 2026

Impact of EGFR variant allele frequency on treatment-related adverse events in patients with metastatic NSCLC treated with osimertinib.

Impact of EGFR variant allele frequency on treatment-related adverse events in patients with metastatic NSCLC treated with osimertinib.

Journal: Frontiers in molecular biosciences

Published: May 11, 2026

Real-World Outcomes of First-Line Pembrolizumab-Based Therapy in Advanced Non-Small-Cell Lung Cancer: A Retrospective Single-Center Study.

Real-World Outcomes of First-Line Pembrolizumab-Based Therapy in Advanced Non-Small-Cell Lung Cancer: A Retrospective Single-Center Study.

Journal: Journal of clinical medicine

Published: April 28, 2026

The Impact of Minimal Residual Disease (MRD) Testing on the Decision-Making Process in Non-Small-Cell Lung Cancer (NSCLC).

The Impact of Minimal Residual Disease (MRD) Testing on the Decision-Making Process in Non-Small-Cell Lung Cancer (NSCLC).

Journal: Cancers

Published: March 16, 2026

Variant allele frequency as a predictor of treatment response to osimertinib in EGFR-mutated NSCLC.

Variant allele frequency as a predictor of treatment response to osimertinib in EGFR-mutated NSCLC.

Journal: Frontiers in molecular biosciences

Published: March 03, 2026

APOBEC mutational signatures predict immune checkpoint inhibitor benefit in TMB-low metastatic NSCLC independent of PD-L1 status.

APOBEC mutational signatures predict immune checkpoint inhibitor benefit in TMB-low metastatic NSCLC independent of PD-L1 status.

Journal: ESMO open

Published: February 26, 2026

Emergence of EGFR C797S as a resistance mechanism to CLN081 in EGFR exon 20-mutant NSCLC: case report.

Emergence of EGFR C797S as a resistance mechanism to CLN081 in EGFR exon 20-mutant NSCLC: case report.

Journal: Frontiers in oncology

Published: February 16, 2026

High-Dose Twice-Daily Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer: A Real-World Retrospective Experience from Two Tertiary Centers.

High-Dose Twice-Daily Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer: A Real-World Retrospective Experience from Two Tertiary Centers.

Journal: OncoTargets and therapy

Published: November 22, 2025

Global advances and future directions in lung cancer care: expert consensus and strategic priorities.

Global advances and future directions in lung cancer care: expert consensus and strategic priorities.

Journal: ESMO open

Published: November 15, 2025

Osimertinib before and after chemoradiotherapy for unresectable stage III EGFR-mutated NSCLC: NEOLA Trial Protocol.

Osimertinib before and after chemoradiotherapy for unresectable stage III EGFR-mutated NSCLC: NEOLA Trial Protocol.

Journal: Future oncology (London, England)

Published: November 14, 2025

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort.

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: November 13, 2025

Showing 1-12 of 199

Last Updated: 09/26/2026